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MITOCHONDRIAL DNA AND CANCER 
 
Cenk Aral, Ayşe Özer 




Mitochondrial DNA has been proposed to be involved in carcinogenesis because of high susceptibility to 
mutations and limited repair mechanisms in comparison to nuclear DNA. In this paper, we review 
mitochondrial genome instability, relation of mitochondrial DNA mutations with apoptosis and 
mitochondrial genomic aberrations reported in solid tumors of the thyroid, colorectal, breast, and gastric 
cancers. 
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Mitokondriyal DNA' nın, nükleer DNA' ya kıyasla mutasyonlara daha duyarlı olması ve tamir 
mekanizmalarının sınırlılığı nedeniyle karsinogenezde rol aldığı öne sürülmüştür. Bu derlemede tiroid, 
kolorektal, meme ve gastrik kanserlerde, mitokondriyal genom kararsızlığı, mitokondriyal DNA 
mutasyonlarının apoptozis ile ilişkisi ve mitokondriyal genomdaki değişimler değerlendirilmiştir. 
 
Anahtar Kelimeler: Mitokondriyal DNA, Genomik kararsızlık, Apoptozis, Mutasyon, Solid tümörler 
 
The abbreviations used are: 8-oxodG, 8-
oxodeoxyguanine; AIF, apoptosis-inducing 
factor; ATP, adenosine-3-phosphate; CD, 
common deletion; CRC, colorectal 
carcinoma; DAP3, death associated protein 3; 
DL, ductal lavage; D-loop, displacement loop; 
FA, follicular adenoma; FNA, fine needle 
aspirate; LOH, loss of heterozygosity; MMR, 
mismatch repair; MSI, microsatellite 
instability; MSNT, matched surrounding 
normal tissue; mt, mitochondrial; mtDNA, 
mitochondrial DNA; mtGI, mitochondrial 
genome instability; mtMSI, mitochondrial 
microsatellite instability; nDNA, nuclear 
DNA; NGI, nuclear genome instability; 
OXPHOS, oxidative phosphorylation system; 
POL γ, DNA polymerase γ; PTC, papillary 
thyroid carcinoma; RFLP, restriction 
fragments lenght polymorphism; ROS, 
reactive oxygen species; SSM, slipped-strand 
mispairing; TFAM, mitochondrial 
transcription factor A; TRAIL, TNF-related 
apoptosis-inducing ligand. 
INTRODUCTION 
Malignant cell transformation is a multistep 
process that usually involves a cascade of 
events in which the sequential malfunction of 
oncogenes, tumor suppressors, mismatch 
repair (MMR) genes and telomere replication 
regulators generate changes in the cell cycle. 
Recently, alterations of mitochondrial DNA 
(mtDNA), which were not found in normal 
tissues from the same individual, have been 
reported in many tumors. In this review, we 
will focus on the current knowledge on the 
role of these alterations in the carcinogenesis 
of human tissues. 
 
1. Mitochondrial genome 
 
Human cells have hundreds of mitochondria 
which are semi-autonomously functioning 
organelles producing cellular ATP as power 
plants of the cell. Each cell contains varying 
numbers of mitochondria depending on 
energetic requirements. The human oocyte is 
estimated to contain 100,000 mitochondria, 
while spermatozoa have relatively few. Each 
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mitochondrium contains a number of copies 
of its own genome (10 to more than 1000) 
whose complete sequence was reported in 
19811,2. Human mitochondrial DNA is a 
double stranded, supercoiled, circular 
molecule, which consists of 16,568 base pairs. 
The compact mtDNA molecule encodes 37 
genes; 13 of them encode polypeptides of the 
oxidative phophorylation system (OXPHOS), 
22 tRNAs and two types of rRNAs. The 
OXPHOS consists of five large enzymatic 
complexes and is formed from the gene 
products of 74 nuclear genes and 13 
mitochondrial genes (Fig 1) (Table I). The 
two complementary strands of mtDNA, based 
on their guanine (G) content, are named as 
heavy and light strands (H-strand and L-
strand, respectively). Guanine-rich H-strand 
of mtDNA encodes 28 of the 37 genes while 
L-strand encodes the remaining genes2,3. A 
non-coding control region extending from 
16,024 to 576 nucleotide positions contains 
three conserved sequence blocks and a 
displacement loop (D-loop). Moreover, 
promoters and enhancers for mitochondrial 
transcription, as well as the origin of 






































Figure 1: Human mitochondrial DNA3. 
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Mitochondria are the major intracellular 
producers of reactive oxygen species (ROS) 
as a side-product of OXPHOS. Deficiency in 
the OXPHOS reduces energy supply and 
enhances ROS production that may induce 
mutation and oxidative damage to mtDNA. 
This increase in the ROS concentration of 
mitochondrial microenvironment gives rise to 
a rate of mitochondrial genome mutations 10 
to 100 fold higher than the nuclear DNA 
(nDNA) mutation rate. Moreover, in contrast 
to nDNA, mtDNA does not contain protective 
histon proteins and intronic sequences. 
However, it has been reported that 
mitochondrial transcription factor A (TFAM) 
is bound to mtDNA and forms histone-like 
structures4,5. In addition, mtDNA repair is 
poor and the replication process is error prone 
when compared to nDNA. Given the high 
copy number of mtDNA per cell, mutated 
mtDNA can be found together with wild-type 
mtDNA. This phenomenon is called as 
heteroplasmy. At the homoplasmic state, there 
is a single type of mtDNA existing in a cell. 
Clinical expression of a given mtDNA 
mutation mainly depends on the proportion of 
mutated and wild-type mtDNAs at the 
heteroplasmic state. Depending on the 
energetic demands of a particular cell, the 
level of mutated genomes is required to 
produce a phenotypic expression (threshold 
effect)6. 
1.1. Reactive oxygen species (ROS) and 
mtDNA 
As noted above, mitochondria are the main 
targets for ROS, which are produced by 
themselves. Oxidative damage to DNA results 
in the base or sugar adducts, single and 
double strand breaks, as well as cross-links to 
other molecules. Many of these mtDNA 
modifications are mutagenic, and thought to 
contribute to cancer, aging and 
neurodegenerative diseases7. More than 20 
base lesions have been identified as a result of 
hydroxyl radical attack. Thymine glycol, the 
most common pyrimidine lesion, has been 
determined to block replication and 
transcription rather than to cause 
mutagenesis8. Generally, hydroxyl radicals 
produce purine modifications. The most 
common and extensively studied purine 
modification is 8-oxodeoxyguanine (8-
oxodG) and it has been found to cause GC → 
TA transversions9. The mtDNA polymerase γ 
(POL γ) also introduces this signature 
mutation at high frequency when replication 
pasts 8-oxodG10. Since increased formation of 
ROS-related DNA modifications has been 
reported in various studies with human 
cancers, it is not clear whether over-
production of ROS is a result or consequence 
of neoplastic transformation11. On the other 
hand, the effect of ROS on mitochondria may 
result in deficiency in the apoptotic behaviour 
of cells and mitochondrial genome instability 
(mtGI) as well as nuclear genome instability 
(NGI), which are the main molecular events 
frequently observed in malignant cells11, as 
will be discussed below. 
Mitochondrial DNA undergoes fragmentation 
and degradation in the mt-environment or in 
the cytoplasm followed by severe damage. In 
some cases, transposition of mtDNA 
fragments within the nuclear genome is 
detected, which may be responsible for 
malign transformation in certain cases of cell 
transformation12. 
1.2. Mitochondrial genome instability 
High rates of spontaneous mutations, 
epigenetic factors such as abnormal 
methylation and loss of heterozygosity (LOH) 
in MMR gene/s explain nuclear genome 
instability in several types of hereditary and 
sporadic human tumors. So far, different rates 
and types of mitochondrial genome instability 
have been analyzed in almost all human 
tumors, but the information is still insufficient 
to explain the role of the mtGI in the origin 
and evolution of human cancers. Since DNA 
damage, slipped-strand mispairing (SSM) and 
defective DNA repair generate the genomic 
changes detected for the nDNA of tumors, it 
has been suggested that these three 
mechanisms are also involved in the 
formation of mtDNA mutations. 
 
Mitochondrial DNA contains several mono- 
and dinucleotide repeats. (CA)n microsatellite 
starts from 514 bp position of the D-loop and 
it shows different alleles varying in size by 
one repeat in human populations. 
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Homopolymeric C tract extends from 16,184 
to 16,193 bp of the D-loop, which is 
interrupted by a T at 16,189 bp position. 
 
It has been proposed that the enhanced 
sensitivity to ROS and lipid peroxides due to 
the triple stranded DNA structure and 
attachment to the mt-membrane of the D-loop 
region may explain the increased rate of the 
D-loop point mutation in breast cancer13. 
 
The first step leading to allelic changes in 
homopolymeric tracts and microsatellites is 
the misalignment of repeats in complementary 
DNA strands with the formation of single 
strand loops of one or more bases14,15. SSM is 
an intra-helical event involving the 
misalignment of repeats in complementary 
DNA strands. The mechanism producing the 
allelic changes in breast cancer (CA)n 
microsatellite can be explained by SSM13.  
 
The chance of alignment shifting is higher for 
homopolymeric or dinucleotide repeats than 
for repeats of three or more base pairs and 
higher for continuous homopolymers than for 
homopolymers interrupted by a base different 
from the repeated one16. Moreover, the cause 
of the homopolymeric tract instabilities have 
been detected in colorectal, gastric and breast 
cancers13,17-19. 
 
The pairing between two direct repeats 
separated by an intervening DNA fragment is 
one of the mechanisms producing mt-
deletions. During this SSM, the intervening 
segment forms single strand loops and 
becomes thereafter deleted, including in the 
deletion of one of the repeats20-24. 
Accordingly, this is the mechanism for the 
4997 bp deletion in breast cancer20 and the 50 
bp deletion in gastric carcinomas25. 
 
It is very well known that defective DNA 
repair is always a component of the 
mechanisms leading to DNA changes. A 
homozygous defective function of one or 
more MMR genes plays an important role in 
malignant transformation. Since MMR gene 
defect shows a marked positive correlation 
with high-frequency of microsatellite 
instability (MSI)26,27, there is no correlation 
between mtMSI and mtGI in colorectal17,18 
and mammary cancers13. These results 
indicate that NGI and mtGI in these tumors 
respond to different mechanisms of defective 
repair. 
 
POL γ is encoded by nuclear genes as all 
other proteins required for mt-genome 
replication28. It is responsible for mtDNA 
replication and error prone due to a 
ineffective proofreading efficiency29,30. Thus, 
probably most forms of mt-genome mutations 
are explained by increased DNA damage plus 
normal POL γ DNA synthesis. It has been 
proposed that the rate of mtDNA mutations is 
increased when POL γ is defected due to 
Protein 
complex 




I ND1, ND2, ND3, ND4, ND4L, ND5, ND6 7 36 
II - 0 4 
III Cytochrome b 1 10 
IV Cytochrome c oxidase I, II and III 3 10 
V ATPase 6 and 8 2 14 
Total 13 74 
Table I: Number of mitochondrial and nuclear DNA-encoded gene products of electron respiratory chain67. 
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mutations, epigenetic factors or inhibition by 
certain antiviral drugs31-33. Zeviani et al.34 
proposed that mitochondrial topoisomerases I 
and II genes are additional causes of mtGI in 
tumors. 
1.3. Mitochondrial DNA mutations and 
apoptosis 
Mitochondria play an important role in the 
apoptotic processes. At the intrinsic pathway 
of apoptosis (e.g. apoptosis due to internal 
signals such as DNA damage), the first step is 
the induction of pro-apoptotic (BAX, BID, 
BAD, NOXA, PUMA) and the down-
regulation of antiapoptotic (Bcl-2, Bcl-xL, 
Bfl-1) Bcl family proteins. The second step is 
the formation of pores in the mitochondrial 
membrane and release of several 
mitochondrial proteins such as cytochrome c, 
SMAC/Diablo and apoptosis-inducing factor 
(AIF) to cytoplasm. These factors then form 
large apoptosome complexes, which lead to 
caspase activation and then apoptosis.The 
contribution of mtDNA mutations to the 
apoptotic behaviour of cells is a great interest 
of research. 
 
Recently, Lee et al.35 have reported that the 
resistance against apoptosis, when induced by 
TRAIL (TNF-related apoptosis-inducing 
ligand), was increased in the cells with 
diminished mitochondrial function Thus, it 
has been suggested that mutations in 
mitochondrial genes might serve as a 
selection advantage over normal cells with 
intact mitochondrial function. In contrast, Liu 
et al.36 have reported that mutation or 
depletion of mtDNA increased the 
susceptibility of the cell to apoptosis, induced 
with strausporin. Moreover, Shidara et al.,37 
investigated the contribution of mtDNA 
mutations in tumor development and 
progression. In this study, cybrids containing 
a single nucleotide mutation at mitochondrial 
ATPase6 gene were inoculated to nude mice, 
which demonstrated higher rates of tumor 
development and progression, compared to 
wild-type mice. Furthermore, they reported a 
lower frequency of apoptotis at cybrids both 
in vivo and in vitro and concluded that 
mutations at the mitochondrial genome offer 
an advantage to cells for promoting 
tumorigenesis, especially at the early stages. 
On the other hand, Schoeler et al.,38 reported a 
relatively higher sensitivity to TRAIL induced 
apoptotic stimuli at cybrid cells with low 
levels of mtDNA 4977 bp common deletion 
(CD). Controversial results obtained by 
various laboratories may be due to 
experimental differences such as cell lines 
used and types of apoptotic induction. 
 
Since a lot of studies revealed these findings, 
molecular mechanisms underlying the effect 
of mtDNA mutations on apoptosis are still a 
mystery. It has been found that the mtDNA 
mutations induce protective expression of 
Bcl-2 and Bfl-1, prosurvival proteins in 
cardiac myocytes39. Park et al.,40 reported an 
increase in the expression of antioxidant 
enzymes at mitochondria depleted cells. They 
suggested that this adaptive response in the 
gene expression renders cancer or aged cells 
with aberrant mtDNA mutations, resists 
against oxidative stress, hosts anti-cancer 
surveillance against chemotherapeutic agents, 
conferring survival advantage. 
 
Jacques et al.,41 showed that expression of 
DAP3 (Death associated protein 3) is strongly 
dependent on mtDNA maintenance. DAP3 is 
a component of the mitochondrial ribosome 
small subunit and a major positive mediator 
of apoptosis. According to their data, DAP3 
was not expressed at mtDNA-less cells, which 
exhibited a relative resistance to apoptosis 
induced with drugs such as strausporin. In the 
mtDNA-less cells 12S and 16S rRNAs 
expression is low and this may  result in a 
failure to assembly mitochondrial ribosomes. 
The authors concluded that mutations of 
mtDNA, resulting in lower rRNA expression, 
might be responsible for apoptotic resistance 
in diseased cells. 
 
2. Mitochondrial DNA mutations and 
cancer 
2.1. Thyroid cancer 
Using two-dimensional gene scanning 
technique, Yeh et al.,42 examined 21 cases of 
thyroid tumors [1 Hurtle cell carcinoma, 4 
follicular adenomas (FA), 13 papillary thyroid 
carcinomas (PTC), 1 follicular carcinoma, 1 
insular carcinoma and 1 medullary 
carcinoma], 6 cases with non-neoplastic 
thyroid pathology, 30 control tissues, 9 foetal 
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thyroid tissue and 9 non-thyroid tissues for 
mtDNA mutation. They identified 3 somatic 
missense mutations in 23% of the papillary 
thyroid cancer cases. These three mutations 
were found in tRNAasp, ND3 and CYT B 
genes. Moreover, sequence variations in both 
neoplastic and non-neoplastic thyroid tissues 
were identified, and the authors concluded 
that these non-somatic variations may be 
related to tumour progression in the thyroid. 
 
Maximo et al.,43 investigated the existence of 
4977 bp common deletion in 79 benign and 
malignant thyroid tumors (Hurtle and non-
Hurtle cell neoplasms). They found mtDNA 
CD in all of the Hurtle cell tumors (100%), in 
33.3% of adenomas and 18.8% of papillary 
carcinomas without Hurtle cell features. The 
authors also found 57 somatic mutations, 
mostly transitions, in coding genes including 
tRNA genes of tumor samples. Follicular and 
papillary carcinomas displayed a significantly 
higher prevalance of mutations of complex I 
genes than follicular adenomas. On the other 
hand, the prevalance of OXPHOS mutations 
in Hurtle cell tumors did not statistically 
differ from non-Hurtle cell tumors. 
 
Rogounovitch et al.,44 investigated mutations 
in mtDNA samples of PTC and FA patients 
from regions  contaminated with 
radioisotopes after the Chernobyl accident. 
Common deletion (4977 bp) was quite 
prevalent in PTC and FA, therefore it was 
unlikely to be representative of thyroid 
tumors. The authors also reported that large 
scale deletions other than CD were higher in 
radiation associated tumors as well as CD 
when compared to the non-radiation 
associated group (spontaneous PTC or FA). 
 
Sequence alterations in the D-loop region of 
mtDNA were also investigated in thyroid 
cancer, as well as other types of human 
cancers. Tong et al.,45 investigated D310 
polymorphisms of the D-loop region. This 
region consists of two cytosine stretches 
interrupted by a thymidine nucleotide 
(C7TC5). Alterations of the cytosine number 
at the first stretch were found in 5.7% PTC, 
5.6% medullary carcinomas, 11.1% anaplastic 
carcinomas and 11.1% follicular thyroid 
carcinomas. Another study including thyroid 
cancer patients from Belarus after the 
Chernobyl accident and 40 sporadic thyroid 
cancer patients from Germany showed that 
alterations of D310 region are related to the 
age of patients at the time of surgery, but not 
to the degree of radioactive contamination46. 
Recently, Maximo et al.,47 examined 
sequence alterations in three repetitive regions 
(D310, D514, D568) in malignant and benign 
thyroid tumors. They found that these 
alterations were common in both malignant 
and benign tumors and cannot be considered 
as a marker of malignancy. 
 
In an ongoing research performed in our 
laboratory, we are examining D310 
alterations using restriction fragments length 
polymorphism (RFLP) assay in thyroid cancer 
patients. In this way, enzymatic digestion of 
PCR products of D310 by using BsaXI, it is 
possible to distinguish 7-C carriers at the first 
stretch. Thus BsaXI positive case is identified 
as 7-C carrier whereas BsaXI negative case 
contains more or less than 7-C in this region. 
According to our preliminary data, 16 of 37 
thyroid cancer patients were BsaXI positive 
(eg. 7-C at D310 region) and 20 of 37 patients 
were BsaXI negative. Only one patient 
showed heteroplasmy and there was no 
difference between tumoral and non-tumoral 
tissues. 
 
2.2 Colorectal Cancer 
 
Aikhionbare et al.,48 examined the 
relationship between mtDNA alterations and 
colorectal carcinogenesis in 25 adenomas, 27 
colorectal carcinomas (CRC) and their 
matched surrounding normal tissues (MSNT). 
A total of 38 nucleotide variants were 
identified; however, none of them appeared to 
be a marker for a particular adenoma of CRC. 
Moreover, the numbers of these variants were 
less in precancerous tissues than in CRC. 
They suggested that this may be a useful 
approach for distinguishing the progressive 
stages of colorectal adenomas. 
 
Nishikawa et al.,49 found a higher mtDNA 
mutation rate in the colonic tissues of patients 
with ulcerative colitis than in those of 
inflammatory disease-free patients. They 
suggested that accumulation of mtDNA 
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mutations, as well as nDNA mutations after 
inflammation, may be an indicator of 
carcinogenesis. On the other hand, the authors 
reported the existence of  homoplasmic 
mutations in both inflammatory and non-
inflammatory regions of the colonic mucosa. 
Greaves et al.,50 showed that a mitochondrial 
mutation in a single cryptic cell could be 
dominated in a patch of cryptic tissue of the 
colon by clonal expansion by cryptic fission. 
 
Lee et al.,51 analyzed the D-loop region of 
mtDNA in a variety of human tumors 
including CRC and found sequence 
alterations in 40% of the patients, mostly in 
the D310 region (90%). They also reported a 
significant decrease in the mtDNA copy 
number in 28% of the cases when compared 
to MSNT, especially in the later stages of 
CRC (stage III and IV). The authors 
suggested that D-loop mutations were 
important markers of carcinogenesis, but the 
molecular mechanism by which the mtDNA 
copy number is decreased by cancer-
associated D-loop mutations is not clear. 
However, in another study, D-loop alterations 
were found in only 8% of colorectal cancers 
without a significant relation between the 
stage of the disease and the occurrence of 
mutation52. 
 
Lievre et al.,53 analyzed entire mitochondrial 
genome in 11 CRC patients and found 10 
somatic mutations in seven patients. Most of 
the nucleotide changes (80%) were found in 
the D-loop region, while the remaining were 
in the coding regions (cytochrome c oxidase 1 
and 3). The authors further analyzed D-loop 
region (nt 190-590) in 365 CRC patients and 
found 142 D-loop alterations. Most of these 
alterations (132) were found in the D310 
region. They also reported that 3-year survival 
rate and the efficacy of adjuvant 
chemotherapy were significantly lower in 
patients with D-loop mutations. 
 
Recently, using PCR-based restriction 
fragments length polymorphism assay with 
BsaXI restriction enzyme, we analyzed the 
D310 region in the CRC and MSNT samples, 
as well as in the samples from healthy 
individuals54. Thirty-six percent of the studied 
samples were homoplasmic BsaXI (+) and 
24% were heteroplasmic (BsaXI +/-). No 
significant differences were found between 
CRCs and MSNTs. When we compared the 
BsaXI status of CRC patients with that of the 
healthy controls, a significant difference was 
found. 
 
2.3. Breast cancer 
The D-loop region of 40 breast cancer 
samples and their MSNT were analyzed using 
RFLP analysis13. It was found that 47.5% of 
the cases were mutated in MnlI restriction 
sites representing a 216-fold increase over the 
spontaneous rate in the female germline. 
 
In another study that involved entire mtDNA 
mutation scanning by temporal temparature 
gel electrophoresis (TTGE), 74% of the cases 
(14/19) were found to be mutated55.The 
percentages of these mutations were 3.7%, 
14.8% and 81.5% in rRNA genes, protein 
encoding genes and D-loop region, 
respectively. 
 
The D310 region in the D-loop region of 
mtDNA was also examined by various 
researchers in breast cancer patients. Parrella 
et al.,56 analyzed D310 mononucleotide repeat 
changes in 64 breast tumors and found D310 
alterations in 12 cases (19%). The majority of 
these alterations were 1 or 2 bp insersions or 
deletions of the first stretch of cytosines, 
except the two cases that showed either an 8 
bp or a 9 bp deletion. The same deletion or 
insersions were also found in the 
corresponding fine needle aspirate (FNA) 
specimens when available. The entire 
mitochondrial genome was sequenced in 18 
primary breast tumors and 7 mutations were 
detected in the coding (ND1, ND4, ND5 and 
cytochrome b genes) and non-coding D-loop 
region. Similarly, several studies revealed the 
possibility of the examination of D310 




Zhu et al.,59 scanned mtDNA for large 
deletions in breast cancer tissues, their MSNT 
and in normal breast tissues from women 
without breast cancer. Common deletion of 
mtDNA had similar frequency in both 
cancerous and in normal tissues, whereas 
novel 3,938 bp and 4,388 bp deletions were 
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more frequent in the cancerous tissue than 
observed in MSNT. Therefore, it was 
suggested that these novel deletions may be a 
marker for breast malignancy. Consistent with 
these data, Dani et al.,60 also noticed a lower 
frequency of CD in tumoral tissues including 
breast cancer. 
 
In our recent study54, we examined 25 breast 
cancer specimens for D310 polymorphism 
with RFLP. BsaXI negative cases had lower 
frequency in the breast cancer samples (11/25, 
44%) when compared to the control group 
(27/41, 65.9%), but this difference was not 
statistically significant. 
 
2.4. Gastric cancer 
 
Tamura et al.,61 screened control region of 
mtDNA in 45 Japanese gastric carcinoma 
patients with PCR-single stranded 
conformation polymorphism assay (SSCP) 
and found only two heteroplasmic mutations 
in nucleotide positions 248 and 16,129. In a 
different study, Maximo et al.,62 found a high 
percentage of CD in gastric cancer (53.1%) 
patients and suggested that gastric cancer is 
more prone to have gross genetic alterations 
of mtDNA than to exhibit signs of fine 
genetic instability. 
 
The D-loop and downstream genes 12s 
rRNA-tRNAphe were studied for sequence 
variations in 22 gastric cancer samples and 
their MSNT by direct sequencing. In this 
study, PolyC and (CA)n instabilities were 
demonstrated in the D-loop including the 
D310 region without a significant difference 
between cancerous tissue versus MNST63. 
Moreover, sequence variations in 12s rRNA-
tRNAphe genes and a significant correlation 
between the frequency of these variations and 
the differentiation degree of gastric carcinoma 
were detected. Recently, D310 alterations 
were found in 14 of 94 gastric cancer samples 
without a significant correlation with 
clinicopathological features, such as patient 
age or sex, tumor location, depth of tumor 
invasion and lymph node metastasis52. Lee et 
al.,51 identified sequence alterations in D-loop 
region (mostly in D310) of mtDNA in 51.6% 
of gastric cancer samples. According to their 
data, 54.8% of the gastric cancers had 
significantly decreased mtDNA copy number 
(below 90%) when compared to MSNT. By 
contrast, 22.6% of the samples had 
significantly higher mtDNA copy numbers 
(above 110%). In contrast to colorectal 
carcinomas indicated above, decrease or 
increase of mtDNA copy number appeared to 
be independent of the stage of the disease. 
 
Eigtheen D-loop mutations were reported by 
Zhao et al.,64 in 20 gastric cancer patients. In 
this study, the level of ROS, rate of cell 
apoptosis and proliferation were found to be 
higher in  patients with mutations than those 
in controls. It was concluded that D-loop 
mutations were important in the development 
and progression of gastric cancer through the 
effect of increased ROS. 
 
Wu et al.,65 examined D-loop mutations and 
the presence of CD in 31 gastric cancer 
samples. In this study, 10 of the patients 
showed sequence alterations in the D310 
region and a total of 17 mutations were 
reported, including a case with 3 mutations. 
Approximately half of the mutations were 
reported as homoplasmic. On the other hand, 
CD was found in 10% of the cancerous 
tissues of the patients, whereas it was found in 
55% of the MSNT. It was also shown that 
55% of the patients had significantly 
decreased mtDNA copy number, which was 




Mutations in the mtDNA have been reported 
in almost all forms of primary tumors 
examined. As recently classified by Carew 
and Huang66, (1) the majority of the mutations 
are base substitutions; (2) mutations occur in 
all protein-coding mitochondrial genes; (3) 
the D-loop region is the most frequent site of 
somatic mutations across most tumor types; 
and (4) the presence of homoplasic mutant 
mtDNA in tumors suggests that they may play 
an important role in the development of 
tumors. It is noteworthy that depletion of 
mtDNA is also reported in many kinds of 
cancer67. As discussed above, in addition to 
several case-control studies, there are various 
in vitro studies concerning the molecular 
mechanism(s) of these molecular alterations. 
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In the future, a combination of these studies 
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